👋 hey researchers,
first issue. the month covered: april 2026. and what a month to start on. the FDA cleared an oral GLP-1 in 50 days under a brand-new fast-track voucher, novo got publicly passed in a head-to-head novo itself ran, the largest US-based research-peptide vendor closed its doors on a thursday afternoon, and the BPC-157 cycle on tiktok kept doing what it's been doing for three years now: rotating between healing miracle and 'why hasn't anyone studied this in humans?'
and one piece of news from today: the FDA closed the 503B compounding loophole on the entire GLP-1 class. that's at the top.
we're going monthly from here. first of every month. snacks-style. one read, ten minutes, all sourced. let's go.
the FDA's 503B exclusion proposal.
april 30, 2026: the FDA proposed to formally exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list. comment period runs through june 29, 2026, then it's final.
the proposal targets 503B outsourcing facilities (the larger commercial compounders that make drugs in bulk with or without prescription), not 503A community pharmacies (which work from individual prescriptions for specific patients). 503A pharmacies are unaffected by this notice.
the FDA's stated rationale: there is "no clinical need" for outsourcing facilities to compound these drugs from bulk substances. that's regulator-speak for permanent ineligibility, not the temporary shortage-driven mechanism that opened the loophole back in 2022.
in practice, semaglutide and tirzepatide already weren't on the 503B bulks list and aren't on the shortage list either. so the proposal mostly formalizes the status quo. but the language matters. and adding liraglutide (Saxenda, Victoza) closes a side door that hadn't been formally shut.
foundayo lands.
eli lilly's orforglipron (brand name Foundayo) became the first oral small-molecule GLP-1 approved by the FDA on april 1, 2026. not a peptide. that distinction matters: peptide orals like rybelsus need permeation enhancers and morning-fast rituals. small molecules absorb cleanly. no fasting requirement, no sip-of-water dance, predictable PK.
ATTAIN-1 phase 3 readout: 12.4% mean weight loss (27.3 lbs) at 72 weeks on the 36mg dose. tirzepatide still beats that on raw efficacy, but foundayo competes against a different set: rybelsus (the only other oral) and the empty shelf of oral weight-loss drugs that came before.
the FDA approved it under the new Commissioner's National Priority Voucher program, 50 days after filing. that's about 4-5x faster than standard review.
cagrisema fails non-inferiority.
late-april refresher of news that broke in february and is still moving the market: novo's cagrisema (a fixed-dose semaglutide + cagrilintide combo) lost a head-to-head against tirzepatide 15mg in REDEFINE-4. 23.0% vs 25.5% body weight reduction at 84 weeks. open-label. failed the non-inferiority primary.
NVO sold off sharply on the readout day and recovered some of it through april as analysts re-rated to a 'tolerability story, not peak-efficacy story.' which is a real story, just a smaller one.
peptide sciences quits.
peptide sciences, the largest US-based research-peptide vendor by public traffic estimates, posted a 'we're closing' notice on their site march 6 and shut by the end of the month. no lawsuit, no public FDA action. just a notice.
context: may 2025 was when the OFA v FDA tirzepatide ruling stood on appeal. compounding pharmacies couldn't make tirzepatide for human use anymore. that was tier-1 enforcement. tier-2 is the gray market: research-grade vendors selling 'not for human consumption' vials. through 2025-2026 the FDA escalated against them via a steady cadence of warning letters and occasional enforcement actions against named vendors.
peptide sciences wasn't named in any public action. they read the room and walked.
quiz answer: eli lilly. foundayo (orforglipron) approved april 1, 2026.
reptides editorial · research reference, not medical advice.